| AhR | Aryl Hydrocarbon Receptor |
| AIEC | Adherent-Invasive Escherichia coli |
| AMP | Antimicrobial Peptide |
| ASCA | Anti-Saccharomyces cerevisiae Antibody |
| BA | Bile Acid |
| BSH | Bile Salt Hydrolase |
| CD | Crohn’s disease |
| CDAI | Crohn’s Disease Activity Index |
| CDEIS | Crohn’s Disease Endoscopic Index of Severity |
| CI | Confidence interval |
| DCA | deoxycholic acid |
| ESBL | Extended-spectrum β-lactamase |
| FFAR | free fatty acid receptor |
| FMT | Fecal microbiota transplantation |
| FXR | Farnesoid X Receptor |
| IBD | Inflammatory Bowel Disease |
| IL | Interleukin |
| IFN-γ | Interferon-gamma |
| JAK | Janus-kinase |
| LBP | Live Biotherapeutic Product |
| LCA | lithocholic acid |
| MDRO | Multidrug-resistant organism |
| NF-κB | nuclear factor kappa B |
| NNT | Number Needed to Treat |
| OR | Odds Ratio |
| rCDI | Recurrent Clostridioides difficile Infection |
| RCT | Randomized Controlled Trial |
| RD | Risk Difference |
| ROS | Reactive Oxygen Species |
| RR | Risk Ratio |
| SCFA | Short-Chain Fatty Acid |
| TGF-β | Transforming Growth Factor Beta |
| TGR5 | Takeda G Protein-Coupled Bile Acid Receptor 1 |
| Th1 | T Helper Type 1 Cell |
| Th17 | T Helper Type 17 Cell |
| Treg | Regulatory T cell |
| UC | Ulcerative Colitis |
| UDCA | Ursodeoxycholic Acid |
| ZO-1 | Zonula Occludens-1 |